USD10
COGT acciones
Acerca de Cogent BiosciencesCogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
USD10
COGT acciones
Acerca de Cogent BiosciencesCogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
Estadísticas
VENTANA DE OPERACIÓN
Cerrado
ABRE A LAS
No hay suficientes datos
CAPITALIZACIÓN DE MERCADO
5541,55 M US$
PRECIO DE APERTURA
36,10 US$
BAJO (1Y)
3,72 US$
ALTO (1Y)
43,73 US$
BAJO (24H)
35,78 US$
Alza (24H)
37,01 US$
Volumen (24 h)
1,54 M US$
31,85 %
Historial de precios
Time | Price | Change |
|---|---|---|
Hoy | 36,10 US$ | 0,00 % |
1 día | 36,10 US$ | 0,00 % |
1 semana | 33,35 US$ | |
1 mes | 39,52 US$ |